Barclays raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $59 from $41 and keeps an Equal Weight rating on the shares after Acelyrin (SLRN) announced results from Part B of a Phase 2b/3 trial evaluating izokibep for the treatment of moderate-to-severe hidradenitis suppurativa. The firm says Acelyrin’s data, a potential competitor to MoonLake, disappointed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MLTX:
- Acelyrin down 62% to $10.55 after izokibep did not meet study endpoint
- MoonLake Immunotherapeutics to hold capital markets day
- Acelyrin price target raised to $39 from $29 at Morgan Stanley
- MoonLake Immunotherapeutics files $1B mixed securities shelf
- Palantir downgraded, Shopify upgraded: Wall Street’s top analyst calls